The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Early antibody therapy can induce long-lasting immunity to SHIV
Open accessAbstract
Highly potent and broadly neutralizing anti-HIV-1 antibodies (bNAbs) have been used to prevent and treat lentivirus infections in humanized mice, macaques, and humans. In immunotherapy experiments, administration of bNAbs to chronically infected animals transiently suppresses virus replication, which invariably returns to pre-treatment levels and results in progression to clinical disease. Here we show that early administration of bNAbs in a macaque simian/human immunodeficiency virus (SHIV) model is associated with very low levels of persistent viraemia, which leads to the establishment of T-cell immunity and resultant long-term infection control. Animals challenged with SHIVAD8-EO by mucosal or intravenous routes received a single 2-week course of two potent passively transferred bNAbs (3BNC117 and 10-1074 (refs 13, 14)). Viraemia remained undetectable for 56–177 days, depending on bNAb half-life in vivo. Moreover, in the 13 treated monkeys, plasma virus loads subsequently declined to undetectable levels in 6 controller macaques. Four additional animals maintained their counts of T cells carrying the CD4 antigen (CD4+) and very low levels of viraemia persisted for over 2 years. The frequency of cells carrying replication-competent virus was less than 1 per 106 circulating CD4+ T cells in the six controller macaques. Infusion of a T-cell-depleting anti-CD8β monoclonal antibody to the controller animals led to a specific decline in levels of CD8+ T cells and the rapid reappearance of plasma viraemia. In contrast, macaques treated for 15 weeks with combination anti-retroviral therapy, beginning on day 3 after infection, experienced sustained rebound plasma viraemia when treatment was interrupted. Our results show that passive immunotherapy during acute SHIV infection differs from combination anti-retroviral therapy in that it facilitates the emergence of potent CD8+ T-cell immunity able to durably suppress virus replication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Koup, R. A., Safrit, J. T., Cao, Y., Andrews, C. A., McLeod, G., Borkowsky, W., Farthing, C., & Ho, D. D. (1994) · Journal of Virology · doi:10.1128/jvi.68.7.4650-4655.1994 · Cited by 2,495
Self-citationBorrow, P., Lewicki, H., Hahn, B. H., Shaw, G. M., & Oldstone, M. B. (1994) · Journal of Virology · doi:10.1128/jvi.68.9.6103-6110.1994 · Cited by 1,882
Brenchley, J. M., Schacker, T. W., Ruff, L. E., Price, D. A., Taylor, J. H., Beilman, G. J., Nguyen, P. L., Khoruts, A., Larson, M., Haase, A. T., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040874 · Cited by 1,832
Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding
Scheid, J. F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T. Y. K., Pietzsch, J., Fenyo, D., Abadir, A., Velinzon, K., et al. (2011) · Science · doi:10.1126/science.1207227 · Cited by 1,139
Self-citationSáez-Cirión, A., Bacchus, C., Hocqueloux, L., Avettand-Fenoel, V., Girault, I., Lecuroux, C., Potard, V., Versmisse, P., Melard, A., Prazuck, T., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003211 · Cited by 1,011
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine
Hansen, S. G., Ford, J. C., Lewis, M. S., Ventura, A. B., Hughes, C. M., Coyne-Johnson, L., Whizin, N., Oswald, K., Shoemaker, R., Swanson, T., et al. (2011) · Nature · doi:10.1038/nature10003 · Cited by 988
Self-citationDavey, R. T., Bhat, N., Yoder, C., Chun, T.-W., Metcalf, J. A., Dewar, R., Natarajan, V., Lempicki, R. A., Adelsberger, J. W., Miller, K. D., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15109 · Cited by 849
Self-citationChun, T.-W., Engel, D., Berrey, M. M., Shea, T., Corey, L., & Fauci, A. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8869 · Cited by 846
Self-citationViraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
Caskey, M., Klein, F., Lorenzi, J. C. C., Seaman, M. S., West, A. P., Buckley, N., Kremer, G., Nogueira, L., Braunschweig, M., Scheid, J. F., et al. (2015) · Nature · doi:10.1038/nature14411 · Cited by 767
Self-citationBarouch, D. H., Whitney, J. B., Moldt, B., Klein, F., Oliveira, T. Y., Liu, J., Stephenson, K. E., Chang, H.-W., Shekhar, K., Gupta, S., et al. (2013) · Nature · doi:10.1038/nature12744 · Cited by 644
Self-citation
Cited by
A perspective on potential antibody-dependent enhancement of SARS-CoV-2
Arvin, A. M., Fink, K., Schmid, M. A., Cathcart, A., Spreafico, R., Havenar-Daughton, C., Lanzavecchia, A., Corti, D., & Virgin, H. W. (2020) · Nature · doi:10.1038/s41586-020-2538-8 · Cited by 485
CD8+ T cells in HIV control, cure and prevention
Collins, D. R., Gaiha, G. D., & Walker, B. D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0274-9 · Cited by 303
CD8 T cells contribute to vaccine protection against SARS-CoV-2 in macaques
Liu, J., Yu, J., McMahan, K., Jacob-Dolan, C., He, X., Giffin, V., Wu, C., Sciacca, M., Powers, O., Nampanya, F., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abq7647 · Cited by 132
HIV-1 cell-to-cell transmission and broadly neutralizing antibodies
Dufloo, J., Bruel, T., & Schwartz, O. (2018) · Retrovirology · doi:10.1186/s12977-018-0434-1 · Cited by 69
Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure
Armani-Tourret, M., Bone, B., Tan, T. S., Sun, W., Bellefroid, M., Struyve, T., Louella, M., Yu, X. G., & Lichterfeld, M. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01010-8 · Cited by 67
Metadata
- Authors
- Nishimura, Y., Gautam, R., Chun, T.-W., Sadjadpour, R., Foulds, K. E., Shingai, M., Klein, F., Gazumyan, A., Golijanin, J., Donaldson, M., Donau, O. K., Plishka, R. J., Buckler-White, A., Seaman, M. S., Lifson, J. D., Koup, R. A., Fauci, A. S., Nussenzweig, M. C., & Martin, M. A.
- Venue
- Nature
- Published
- 2017-03
- Volume
- 543
- Issue
- 7646
- Pages
- 559-563
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2597074085
- Cited by
- 312
- References
- 34
- FWCI
- 18.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early antibody therapy can induce long-lasting immunity to SHIV. https://app.cochat.ai/papers/10.1038/nature21435
- The paper
- Nishimura, Y., Gautam, R., Chun, T.-W., Sadjadpour, R., Foulds, K. E., Shingai, M., Klein, F., Gazumyan, A., Golijanin, J., Donaldson, M., Donau, O. K., Plishka, R. J., Buckler-White, A., Seaman, M. S., Lifson, J. D., Koup, R. A., Fauci, A. S., Nussenzweig, M. C., & Martin, M. A. (2017). Early antibody therapy can induce long-lasting immunity to SHIV. Nature. https://doi.org/10.1038/nature21435
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
